Tris Pharma Announces Acceptance of Its First Two NDAs

... - First ever 24 hour oral liquid sustained release formulation submitted to the ... and films - Upon approval will provide both liquid and tablet forms as alternative to current ... a cardiovascular drug. If approved, Tris Pharma's liquid and solid dosages will provide an alternative to ...

Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease

... new drug application to evaluate GAMMAGARD liquid [Immune Globulin Intravenous (IGIV)], marketed as ... filing for regulatory approval for GAMMAGARD liquid as a potential treatment for the disease. The ... for the Phase I and II studies with GAMMAGARD liquid for the same indication. ...

NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation

... is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized ... in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We ... is a topically applied, high-concentration liquid formulation of capsaicin designed to treat pain ...

Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)

... examining an oral administration of the current liquid injectible dose form of 4-MP that is marketed in ... dose escalation study of this orally administered liquid 4-MP or placebo, concomitant with ethanol. ... and conclude the Phase IIa study of the liquid injectible dose form of 4-MP. These statements ...

Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimer's Disease Announced

... patients treated with GAMMAGARD S/D and GAMMAGARD liquid [Immune Globulin Intravenous (IGIV)] for the ... the primary endpoint criteria favoring GAMMAGARD liquid and GAMMAGARD S/D over placebo on measures of ... patients treated with GAMMAGARD S/D and GAMMAGARD liquid compared to placebo. Twelve-to-18 month data ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... administration of a monthly dose of GAMMAGARD liquid in patients with Primary ... infusion (under the skin) of GAMMAGARD liquid [Immune Globulin Intravenous (Human)] (IGIV) ... (AAAAI) in Philadelphia, PA. GAMMAGARD liquid is approved for intravenous administration, which ...

Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained With Naproxen Sodium

... of Medicine. About ALEVE and ALEVE liquid Gels Since its introduction as an OTC product in ... pain reliever for more than a decade. ALEVE liquid Gels, launched in March 2007, were developed to ... day relief with just two pills, ALEVE and ALEVE liquid Gels can be used for the treatment of aches and ...

Baxter and The Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimer's Disease

... Phase III study evaluating the role of Gammagard liquid [Immune Globulin Intravenous (Human)] (IGIV), an ... with primary immunodeficiency. GAMMAGARD liquid is processed from large pools of human plasma. ... in the U.S. that are members of ADCS. GAMMAGARD liquid [Immune Globulin Intravenous (Human)] 10% ...

Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skin's Natural Moisture

... require different care than skin proteins, Dove developed its latest liquid cleansing technology called NutriumMoisture. Research published in the ... has allowed us to be the first brand to minimize lipid damage with a liquid cleanser in order to provide intensive moisturizing benefits that ...

IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile

... into interior (intramedullary canal) of the bone. A light sensitive, liquid monomer is then infused into the balloon, expanding the balloon to fit the ... interior of the bone. Then the light source is activated, converting the liquid monomer into a hardened polymer within 90 seconds. The tiny skin incision ...

White Paper Explains Aspects of Testing From Purified Bulk Drug Substance to Sterile Liquid Final Drug Product

... " Where and What to Test: From Purified Bulk Drug Substance to Sterile liquid Final Drug Product, " focuses on what many consider the most critical ... " Where and What to Test: From Purified Bulk Drug Substance to Sterile liquid Final Drug Product, " visit: ...

Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms

... system and among about 25 hospitals nationally that are using a glue-like liquid for the successful treatment of brain aneurysms without surgery. In a ... the right side of a patient's head. Called Onyx(R)HD 500, the glue-like liquid is delivered through a micro-catheter, a thin, tube-like device that has ...

Valor Medical Reports Early Clinical Results of New Technology to Treat Cerebral Aneurysms

... technology, Neucrylate(TM), to treat cerebral aneurysms. Neucrylate is a liquid embolic that has been developed by Valor Medical, a San Diego, CA, medical ... comes in contact with the blood in the aneurysm it changes from a liquid to a sponge-like material. Once the catheter is in place the treatment ...

Amikacin Inhale Shows Promising Results in Phase II Study

... HealthCare in cooperation with Nektar Therapeutics, combining a special liquid formulation of the aminoglycoside antibiotic amikacin with Nektar Therapeutics' proprietary liquid Pulmonary Technology (LPT(TM)), designed to deliver amikacin deep into the ...

Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm

... catheter that is first inserted in the femoral artery. Neucrylate AN is a liquid that, when it comes in contact with blood, changes into a solid spongy material. The liquid enables the surgeon to totally fill the aneurysm regardless of shape, a ...

Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex

... and the world and innovation in palliative care education. HYLENEX is a liquid injectable drug product formulation that includes the active ... Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD liquid 10%. In addition, the company has received FDA approval for two products: ...

Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study

... proprietary Dri-Sate(R) Dry Acid Concentrate Mixing System, RenalPure(R) liquid Acid Concentrate, SteriLyte(R) liquid Bicarbonate Concentrate, RenalPure(R) Powder Bicarbonate Concentrate, ...

Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study

... proprietary Dri-Sate(R) Dry Acid Concentrate Mixing System, RenalPure(R) liquid Acid Concentrate, SteriLyte(R) liquid Bicarbonate Concentrate, RenalPure(R) Powder Bicarbonate Concentrate, ...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

... Drug User Fee Act (PDUFA) date of August 16, 2009. NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed ...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

... Preliminary research studies show that the test can measure and reproducibly detect as few as 50 DNA copies for each of the 15 HPV genotypes in liquid cytology samples from cervical smears and tissue biopsy samples. The AttoSense test is currently available for Research Use Only. SEQUENOM intends ...

Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc.

... Research Labs, Inc. is being used successfully by city parks, golf courses and individuals all across the country. Mosquito Barrier is a very strong liquid garlic made from very potent garlic cloves which is considerably more potent than the garlic found in grocery stores. Garlic has a natural sulfur ...

ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)

... and is a unique dry powder topical tissue sealant that rapidly stops bleeding after or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: it is ready for immediate use, is stable at room temperature, highly effective and fast acting. ProFibrix expects to submit ...

PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans

... System and eFlow Technology The Investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other ...

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

... Drug User Fee Act (PDUFA) date of August 16, 2009. NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed ...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

... System and eFlow Technology The Investigational eFlow Nebulizer System uses eFlow Technology to enable highly efficient aerosolization of liquid medications via a vibrating, perforated membrane that includes thousands of small holes that produce the aerosol mist. Compared to other ...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

... needs. Agennix's lead molecule, talactoferrin, is an immunomodulatory protein with a novel mechanism of action. The Company is developing an oral liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. Agennix has more than ...

DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms

... formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products. More information: www.dsmpharmaceuticals.com . About DSM Biologics DSM Biologics, a business unit of DSM ...

Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for the Treatment of Urea Cycle Disorders

... including those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100 is dosed orally in liquid form. "Receiving orphan drug designation for HPN-100 in the treatment of urea cycle disorders is an important milestone and provides meaningful ...

American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission

... hand washing and covering your mouth when coughing or sneezing." The American Lung Association advises that hand washing is most effective with liquid soap. Hands should be rubbed vigorously under running water of any temperature for at least 20 seconds. Consider singing the "Happy Birthday" song ...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

... a defective gene disrupts ion transport across the epithelial membrane within cells. In the lungs, this leads to a depletion of the airway surface liquid that normally bathes the cilia, and a resultant reduction in mucociliary clearance. The result is thick, sticky mucus that clogs the lungs, severely ...

Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study

... the primary interventional technologies used today - peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at ....

Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin

... the Xpert MTB/RIF is Cepheid's first test released in the new Reagents on Board configuration. This new test configuration includes the packaging of liquid reagents along with the previously included dry reagents in the test cartridge. This added feature makes the test procedure even easier to perform ...

Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders

... those related to carbamylphosphate synthetase, ornithine transcarbamylase and argininosuccinic acid synthetase. HPN-100, which is dosed orally in liquid form, provides an alternative pathway to the urea cycle for the disposal of waste nitrogen through the renal excretion of phenylacetylglutamine, ...

Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A.

... field of oxygen therapeutics and continuous substrate monitoring. The company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte(R)) and an implantable glucose sensor. These products are based upon core technologies that include biomedical ...

VirtualScopics' Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial

... medicine (tissue repair) and therapeutic delivery. BioSyntech's platform technology is a family of hydrogels called BST-Gel(R), some of which are liquid at low temperature and solid at human body temperature. These gels can be injected or applied to a specific local site and offer beneficial ...

ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell

... topical tissue sealant that stops acute and severe bleeding after trauma injury or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants: It is easier to prepare and use, is more stable and effective, and can be applied in various ways, including in sprays or bandages. ...

NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

... under review by the European Medicines Agency (EMEA). NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 is currently in ...

Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme

... therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD liquid 10%. In addition, the company has received FDA approval for two products: Cumulase, for use in in-vitro fertilization, and HYLENEX, for use as an ...

Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target

... therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD liquid 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an ...

Duska Therapeutics Applies for Phase 3 Special Protocol Assessment

... or pain, weakness, shortness of breath, or dizziness. The heart rate in PSVT can range from 150-250 beats per minute. ATPace, a stable liquid formulation of adenosine 5'-triphosphate (ATP) for intravenous injection, is an investigational drug for the acute termination of PSVT. The ...